The scientist’s investigation covers issues in Internal medicine, Endocrinology, Immunology, Fibrinolysis and Coagulation. The Internal medicine study combines topics in areas such as Gastroenterology and Surgery. Joost C. M. Meijers interconnects Inflammation and Carboxypeptidase B2 in the investigation of issues within Endocrinology.
Joost C. M. Meijers has researched Immunology in several fields, including Venous thrombosis, Antithrombin and Pneumococcal pneumonia. His Fibrinolysis study integrates concerns from other disciplines, such as Coagulopathy, Thrombomodulin, Thrombin, Fibrin and Carboxypeptidase. His Coagulation research includes themes of Thrombosis and Pharmacology.
Joost C. M. Meijers spends much of his time researching Internal medicine, Immunology, Coagulation, Fibrinolysis and Endocrinology. His Internal medicine research integrates issues from Gastroenterology and Cardiology. His study in Immunology is interdisciplinary in nature, drawing from both Hemostasis, Protein C and Tissue factor.
His Coagulation study incorporates themes from Anticoagulant, Anesthesia, Fibrinogen and Pharmacology. His studies in Anesthesia integrate themes in fields like Surgery and Prothrombin time. His Fibrinolysis study combines topics in areas such as Plasmin, Biochemistry, Fibrin, Plasminogen activator and Thrombin.
Joost C. M. Meijers focuses on Internal medicine, Coagulation, Immunology, Fibrinolysis and Thrombin. Joost C. M. Meijers has included themes like Gastroenterology, Endocrinology and Cardiology in his Internal medicine study. His Coagulation study combines topics from a wide range of disciplines, such as Anticoagulant, Anesthesia, Coagulopathy and Pharmacology.
The Immunology study combines topics in areas such as Hemostasis and Lung. His studies examine the connections between Fibrinolysis and genetics, as well as such issues in Fibrinogen, with regards to Fibrin. The concepts of his Thrombin study are interwoven with issues in Peptide, Factor V, Plasmin and Factor V Leiden.
His primary areas of study are Immunology, Fibrinolysis, Internal medicine, Thrombin and Endocrinology. His Immunology research incorporates elements of Bronchoalveolar lavage, Lung, Pneumonia and Tissue factor. His studies deal with areas such as Gastroenterology, Zymogen, Fibrinogen, Coagulation and Von Willebrand factor as well as Fibrinolysis.
He works mostly in the field of Internal medicine, limiting it down to topics relating to Cardiology and, in certain cases, ADAMTS13. His work on Carboxypeptidase B2 as part of his general Thrombin study is frequently connected to Prothrombin complex concentrate, thereby bridging the divide between different branches of science. His work deals with themes such as Coagulation factor XI, Factor IX and Vein, which intersect with Endocrinology.
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
Elise S. Eerenberg;Pieter Willem Kamphuisen;Meertien K. Sijpkens;Joost C. Meijers.
High levels of coagulation factor XI as a risk factor for venous thrombosis.
Joost C.M. Meijers;Winnie L.H. Tekelenburg;Bonno N. Bouma;Rogier M. Bertina.
The New England Journal of Medicine (2000)
Loss of Endothelial Glycocalyx During Acute Hyperglycemia Coincides With Endothelial Dysfunction and Coagulation Activation In Vivo
Max Nieuwdorp;Timon W. van Haeften;Mirella C.L.G. Gouverneur;Hans L. Mooij.
Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation.
Kamran Bakhtiari;Joost C M Meijers;Evert de Jonge;Marcel Levi.
Critical Care Medicine (2004)
KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium
Rob J. Dekker;Reinier A. Boon;Mariska G. Rondaij;Astrid Kragt.
Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis
P. A. K. Von Dem Borne;J. C. M. Meijers;B. N. Bouma.
Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1
Mirjam E. Meltzer;Mirjam E. Meltzer;Ton Lisman;Ton Lisman;Philip G. de Groot;Joost C.M. Meijers.
Ability of Recombinant Factor VIIa to Reverse the Anticoagulant Effect of the Pentasaccharide Fondaparinux in Healthy Volunteers
Nick R. Bijsterveld;Arno H. Moons;S. Matthijs Boekholdt;Benien E. van Aken.
Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo
Marieke A.D. van Zoelen;Huan Yang;Sandrine Florquin;Joost C.M. Meijers.
Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor.
J. A. Koedam;J. C. M. Meijers;J. J. Sixma;B. N. Bouma.
Journal of Clinical Investigation (1988)
If you think any of the details on this page are incorrect, let us know.